[Pharmaceutical care for severe and critically ill patients with COVID-19].

[Pharmaceutical care for severe and critically ill patients with COVID-19].

Publication date: May 25, 2020

Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.

Concepts Keywords
Adverse Drug Reactions Coronaviridae
Antibacterial Antiviral drug
Antiviral Drugs Coronavirus
Biosafety Pharmaceutical industry
Coronavirus Medication
Corticosteroids Pharmacy
Nutrition Articles
Pneumonia Health sciences
Probiotics Medication errors
Zhejiang Diseases

Semantics

Type Source Name
disease MESH critically ill
disease MESH drug interactions
disease MESH medication errors
disease MESH Diagnosis
disease MESH pneumonia
disease MESH adverse drug reactions

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *